About us
Welcome To Biomed JR
Biomed-JR is a dynamic Israeli pharmaceutical company, providing a full range of marketing, sales and professional services to international pharmaceutical and medical device companies.
Biomed-JR operates in the Israeli Bio-Pharmaceutical industry and is dedicated to representing international pharmaceutical partners and premium ethical products approved in Europe, Australia and or USA.
Our goal is to provide quality medications to the healthcare sector and to maximize the potential sales for our partners.
The company is in compliance with accepted standards of Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), Good Promotional Practice (GPP) and ISO 9001.
Our partners
Biomed JR is a growing company representing international companies in Israel and marketing their product to physicians, nurses and pharmacists.
Logistics and market coverage
Biomed JR products are distributed by Novolog Ltd, the largest logistics company in the pharmaceutical industry in Israel, giving our clients the highest international Standards of Good Storage and Distribution Practice (GSP/GDP).Biomed-JR provides full coverage of the Israeli market through its well established relations with the 4 HMO’s and government and private hospitals.
Institution Patient importation
Biomed-JR specializes in specific patient – institution importation treatments not registered in Israel (29c).
Institution Patient Importation provides controlled, pre-approval access to drugs. This is in response to requests by physicians on behalf of specific patients, before those medicines/indications are licensed in Israel or to provide patients access to drugs which are approved in other countries for a genuine, unmet medical need, before those drugs have been licensed locally.
Institution Patient Importation provides controlled, pre-approval access to drugs. This is in response to requests by physicians on behalf of specific patients, before those medicines/indications are licensed in Israel or to provide patients access to drugs which are approved in other countries for a genuine, unmet medical need, before those drugs have been licensed locally.
